Levi & Korsinsky is investigating the Board of Directors of Sunesis Pharmaceuticals, Inc. (“SNSS” or the “Company”) (NASDAQ:SNSS) for possible violations of federal securities laws. The investigation concerns whether SNSS and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On July 23, 2015, SNSS announced that the Food and Drug Administration would require more clinical evidence demonstrating the efficacy of the proposed leukemia treatment vosaroxin before considering its New Drug Application. To obtain additional information, go to:

http://zlk.9nl.com/sunesis-pharmaceuticals-snss

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLPEduard Korsinsky, Esq.Tel: 212-363-7500Toll Free: 877-363-5972Fax: 212-363-7171www.zlk.com

Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Sunesis Pharmaceuticals Charts.
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Sunesis Pharmaceuticals Charts.